Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 16;8(8):ofab385.
doi: 10.1093/ofid/ofab385. eCollection 2021 Aug.

Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019

Emma D Bainbridge  1 , Priscilla Y Hsue  2 , Jonathan H Esensten  3 , Kara L Lynch  3 , Carolyn M Hendrickson  4 , Sarah B Doernberg  1 , Monica Fung  1 , Peter Chin-Hong  1 , Clara Di Germanio  5 , Philip J Norris  3   5 , Graham Simmons  3   5 , David V Glidden  6 , Anne F Luetkemeyer  7
Affiliations

Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019

Emma D Bainbridge et al. Open Forum Infect Dis. .

Abstract

We characterized the antibody composition of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) and the immunologic responses of hospitalized COVID-19 patients after receiving CCP or nonimmune fresh frozen plasma. Despite selection of CCP with significantly higher total immunoglobulin G than recipients, neutralizing antibody levels did not differ between donor plasma and CCP recipients.

Keywords: COVID-19; SARS-CoV-2; antibody avidity; convalescent plasma; neutralizing antibody.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Antibody (Ab) composition of high titer coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) and antibody and viral load dynamics in COVID-19 patients who received CCP or nonimmune fresh frozen plasma (FFP). (A) Immunoglobulin (Ig)A, IgM, IgG, avidity, and neutralizing antibody levels in donor plasma and study participants at baseline (before transfusion). (B) Immunoglobulin A, IgM, IgG, avidity, and neutralizing antibody levels at day 1 and day 29 stratified by CCP and FFP group. (C) Baseline severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quantitative polymerase chain reaction (PCR) cycle threshold by days since symptom onset (r = 0.01). (D) Median SARS-CoV-2 quantitative PCR cycle threshold in CCP recipients compared with FFP recipients at day 1 (before transfusion), day 2, day 5, and day 8. Dotted horizontal lines on each graph denote positivity cutoff for each assay (there is no cutoff for the avidity assay). * = statistically significant, P < .05. r = Pearson correlation coefficient. IC50, inhibitory concentration of 50%; ns, not significant; OD50, optical density 50; RFU, relative fluorescent units; RLU, relative light unit; RVPN, reporter viral particle neutralization; S/CO, signal-to-cutoff ratio.
See this image and copyright information in PMC

References

    1. Hinton DM. FDA convalescent plasma EUA letter of authorization. Available at: https://www.fda.gov/media/141477/download. Accessed 21 April 2021.
    1. Casadevall A, Pirofski L, Joyner MJ. The principles of antibody therapy for infectious diseases with relevance for COVID-19. mBio 2021; 12:e03372–20. - PMC - PubMed
    1. Tang J, Grubbs G, Lee Y, et al. . Impact of convalescent plasma therapy on SARS CoV-2 antibody profile in COVID-19 patients. Clin Infect Dis 2021; ciab317. - PMC - PubMed
    1. Benner SE, Patel EU, Laeyendecker O, et al. . SARS-CoV-2 antibody avidity responses in COVID-19 patients and convalescent plasma donors. J Infect Dis 2020; 222:1974–84. - PMC - PubMed
    1. Robbiani DF, Gaebler C, Muecksch F, et al. . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 2020; 584:437–42. - PMC - PubMed